A meta-analysis confirmed significantly reduced risk for ovarian cancer for BRCA1 (SRR = 0.51; 95% CI 0.40–0.65) and BRCA2 mutations carriers (SRR = 0.50; 95% CI 0.29–0.89) associated with use of OC. This evidence concerns the gene BRCA1 and ovarian carcinoma.